MEDTECH ARCHITECT · MINNEAPOLIS
Great devices fail inside badly designed systems.
Most device failures are not device failures. They are architecture failures: the care pathway, business viability, the data flow and the commercial plan were never designed with the product. I write about how to design them together.
TAVR
Evolut PRO®
Developed and commercialized Medtronic's next-generation TAVR platform.
EU MDR
$1B+ portfolios
Led and guided transition efforts accountable for more than $1B in revenue continuity.
INVENTION
U.S. patent
Inventor in transcatheter valve technology.
QUALITY
ASQ honoree
Named one of the 40 New Quality Voices.
THERAPEUTIC AREAS
Three therapy areas. The same architecture problems.
2010 TO 2020 · MEDTRONIC
Cardiovascular
-
Transcatheter and surgical aortic valves, structural heart
-
Endovascular aortic aneurysm devices
-
From design assurance and Six Sigma to TAVR commercialization and EU MDR
2016 TO 2025 · ADVISORY AND VENTURES
Neuroscience
-
Neurodegenerative disease development, including dementia, sleep, cardio and Alzheimer's
NOW · CONNECTED CARE
Respiratory
-
COPD and asthma care at home
-
Earlier detection and airway clearance
-
Remote monitoring and longitudinal care models
Across all three, the device is rarely the weak point. The care pathway, business viability and the data flow were designed after it instead of with it.
THE APPROACH
In medtech, product-market fit is system fit.
A device can be engineered, validated and FDA cleared and still never find its market. Fit is built in a sequence: start from what clinicians and patients need, make sure it fits how care is delivered, then prove it can be built, paid for and cleared. Each step is cheaper to get right before design freeze and expensive to fix after launch.
STEP
THE FIT QUESTION
WHEN IT'S SKIPPED
01 Clinical and user needs
What outcome do patients, caregivers and clinicians need, stated in their terms rather than as features?
A solution to a problem nobody ranked as urgent.
02 Care pathway fit
Does it fit inside the existing workflow, for the clinician and the patient, without adding work?
Adoption stalls. You're asking clinicians and patients to do extra work they aren't motivated to do.
03 Requirements and architecture
Do the needs translate into system requirements, including the apps, data and devices it has to work with?
Engineering builds what was easy to specify, not what users needed.
04 Feasibility and validation
Has a prototype been in front of the real users, with the big technical risks retired or named?
Risks surface in verification, when every fix costs a schedule slip.
05 Business viability
Is the market sized by segment, the unit cost real, willingness to pay tested and the reimbursement pathway mapped?
Clinically excellent, commercially stranded.
06 Regulatory and evidence pathway
Are the claims drafted early from user needs, with the evidence to support them planned and costed?
Marketing wants a claim that engineering never designed for and no study supports.
Insights
MedTech Architect
I'm Nathan Piland, a medtech executive in Minneapolis with more than 20 years across startups and global leaders. I spent a decade at Medtronic building structural heart devices, from design assurance engineering to launching a TAVR platform and leading a valve portfolio through EU MDR. Since 2016 I've advised startups and growth-stage companies through Strategies for Medtech, led medtech business units at Indegene and RQM+, served as interim CEO of the Nunex joint venture, and worked on neurodegenerative disease at Ciatrix. Today I focus on respiratory and connected care as I feel that's one of the largest disease spaces nagging at our loved ones. I plan to fix it.
EDUCATION
-
MBA, Babson College, F.W. Olin Graduate School of Business
-
M.Eng, Tufts University
-
B.S., Mechanical Engineering, Wentworth Institute of Technology
-
Design for Six Sigma Master Black Belt
COMMUNITY
-
Minnesota Babson Alumni and Incoming Student
-
Go Red for Women supporter, American Heart Association
-
Member, American Thoracic Society (ATS)
NEWSLETTER
The trends that usually go unnoticed.